Rep. Gilbert Ray Cisneros Jr. (D-CA) Buys Zoetis (ZTS) Stock
Rep. Gilbert Ray Cisneros Jr. has made a new purchase in Zoetis Inc.
Reviewed by automated data checks against the source filing. How we make and check alerts
Rep. Gilbert Ray Cisneros Jr. (D-CA) bought between $1,001 and $15,000 of Zoetis Inc. ($ZTS) stock on September 18, 2026. The trade was disclosed in a STOCK Act periodic transaction report filed October 12, 2026.
Since the trade, $ZTS is down 0.5% after 1 week and up 11.2% to date (from the $71.40 close on Sep 18, 2026).
Financial Disclosure Report
Clerk of the House of Representatives • Legislative Resource Center • B81 Cannon Building • Washington, DC 20515
Filer Information
- Name:
- Rep. Gilbert Ray Cisneros Jr. (D)
- Status:
- Member — House
- Party:
- Democrat
Filing Information
- Filing Type:
- Periodic Transaction Report
- Filing Year:
- 2026
- Filing Date:
- Oct 12, 2026
Schedule B: Transactions
| Asset | Transaction | Date | Amount |
|---|---|---|---|
| Zoetis Inc. ($ZTS) | Buy | Sep 18, 2026 | $1,001 - $15,000 |
Summary of the filed report, not the original document. View the original: STOCK Act disclosure (House Clerk)
ZTS
Zoetis Inc.
Key Points
- On September 18, 2026, Rep. Gilbert Ray Cisneros Jr. bought shares of Zoetis Inc. valued between $1,001 and $15,000.
- As of October 16, 2026, Zoetis shares recently traded around $78.96, significantly below the target mean price of $93.47.
- The company, which specializes in animal health products, has a market cap of approximately $32.4 billion.
Get $ZTS trade alerts by text
We text you when insiders, Congress or big funds trade $ZTS. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Zoetis Inc. alert may contain errors. Disclosures
Rep. Gilbert Ray Cisneros Jr., a Democrat from California's 31st district, bought shares of Zoetis Inc. (NYSE: ZTS) on September 18, 2026. This purchase was valued between $1,001 and $15,000, according to a periodic transaction report filed under the STOCK Act on October 12, 2026.
Gilbert Ray Cisneros Jr. vs. the S&P 500
Hypothetical returns from Gilbert Ray Cisneros Jr.'s disclosed trades, not real profit or advice. How we model this.
What Changed in Gilbert Ray Cisneros Jr.'s Zoetis Position
Cisneros Jr.'s recent transaction marks a new investment in Zoetis. This purchase adds to his portfolio as the company focuses on health solutions for animals.
Other Institutional Activity in Zoetis
Several institutional investors have been active in Zoetis recently. Blackrock Inc. increased its stake by 3,846,587 shares, bringing its total to about 39.4 million shares worth approximately $3.13 billion. State Street Corporation also added 343,963 shares, ending with about 19.7 million shares valued at around $1.56 billion. Meanwhile, Vanguard Capital Management LLC and Vanguard Portfolio Management LLC both trimmed their positions slightly, with decreases of 44,323 and 107,857 shares, respectively.
Zoetis Inc. Stock Up 5.4%
Zoetis shares recently traded around $78.96 as of October 16, 2026. This is above the 52-week low of $68.77 but significantly below the 52-week high of $148.30. The stock is currently below its target mean price of $93.47, indicating potential for growth.
Recent Earnings
For the trailing twelve months, Zoetis reported revenue of about $9.53 billion and earnings per share (EPS) of $6.16. The company is scheduled to announce its next earnings on November 5, 2026.
Insider Buying and Selling at Zoetis Inc.
Recently, several insiders have purchased shares of Zoetis. Director Michael B. McCallister bought 3,000 shares at an average price of $77.76 on May 11, 2026. Paul M. Bisaro, also a Director, acquired 2,000 shares at $75.88 on May 13, 2026. The same day, Director Amelio Frank A. D. purchased 6,650 shares at $75.39.
Analysts Set New Price Targets
On August 10, 2026, Piper Sandler maintained a Neutral rating on Zoetis with a price target of $80.00. Citigroup also maintained a Buy rating with a target of $96.00 on August 11, 2026. The consensus among analysts currently suggests a buy recommendation with a mean price target of $93.47 based on 15 opinions.
About Zoetis Inc.
Zoetis Inc. is a leading animal health company that develops and sells medicines, vaccines, and diagnostic products for both companion animals and livestock. With a focus on innovative solutions, Zoetis plays a vital role in the health of animals globally, which is important for food safety and public health.
Bottom Line
Investors should keep an eye on Zoetis as it prepares to report earnings on November 5, 2026. With recent insider buying and institutional interest, the stock may be worth monitoring for further developments.
Related Filing Alerts
Source: Gilbert Ray Cisneros Jr.'s STOCK Act disclosure on $ZTS (Sep 18, 2026). Read the original filing: STOCK Act disclosure (House Clerk). Written by software, not financial advice. How we make alerts